ENKI-OX Scientifically Engineered Enkephalinase Inhibitor --
Indications for analgesia, antidepressant, anxiolytic research, and anti-addiction research.
Warning: Last items in stock!
ENKI-OX Scientifically Engineered Enkephalinase Inhibitor (ENKi) Optimized Extract
ENKI-OX is a centrally acting, moderately potent, orally bioavailable enkephalinase inhibitor optimized extract intended to foster non-addictive analgesic, anxiolytic, and antidepressant efficacy. Using mice in assays modeling for antidepressant and anxiolytic effects, compared to the active reference Selank (i.p. 0.1mg/kg, 0.2mg/kg, i.p.) ENKI-OX demonstrated superior efficacy at oral administrations of 5mg/kg, 10mg/kg, and 20mg/kg.
ENKI-OX as well dramatically decreased PAWS in animal model assays indicating potent post-acute withdrawal syndrome reduction efficacy. In models of analgesic efficacy ENKI-OX promoted significant efficacy, though significantly lower than that of classical mu-opioid agonists.
ENKI-OX demonstrated highly significant potentiation of opioidergic analgesics indicating potent analgesic-sparing/tolerance reducing efficacy.
ENKI-OX was seen to produce superior results with a dosing administration protocol of five consecutive days of administration followed by five and ten consecutive days of washout.
Theorized Human Use Optimized Protocols:
In theory, as an extrapolation from the present animal data, optimium administration for anti-addiction, antidepressant/anxiolytic, and analgesic-sparing indications would comprise 20-80mg q.d. to t.i.d. for courses of 5-10 days with a subsequent washout period of equal time.
Appearance: Brown powder
Solubility: Mostly soluble in hydroethanolic solutions at 40-120mg/ml.
Bulk Purchases: E-mail for details regarding bulk purchases at TLR@teamtlr.com
USAGE: For Research Use Only! Not For Use in Humans